This website is for UK Healthcare Professionals only

This promotional material is intended for UK Healthcare Professionals experienced in the diagnosis and treatment of Chronic Migraine. BOTOX® (botulinum toxin type A) Prescribing Information and adverse event reporting information can be found below.

+30 YEARS' GLOBAL EXPERIENCE
ACROSS MULTIPLE INDICATIONS1-4

 

CHRONIC MIGRAINE

BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5

+30 YEARS' GLOBAL EXPERIENCE ACROSS MULTIPLE INDICATIONS1-4

CHRONIC MIGRAINE

BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5

Chronic migraine: a long and frustrating patient journey6*†

*This journey is based on clinical observations. Patients may have an entirely different experience in their own journey.
Based on a small-scale (N=200) questionnaire-based study of patients presenting with headache.6


Diagnosing and managing chronic migraine


Could your patients with chronic migraine benefit from treatment with BOTOX®?

A real-life patient treatment journey

Kayte was diagnosed with chronic migraine at 24, and experienced issues with certain treatments before finding one that suited her.

Learn about her individual experience in this video, and find out about her experience with BOTOX® >

Initiating a patient on BOTOX®

How should you consult your patients who are starting on BOTOX®, and how can you ensure treatment adherence?

Neurologist Dr Andrew Blumenfeld explains in this 6-minute video >

Find out how to administer BOTOX®

Learn about the PREEMPT treatment paradigm: an evidence-based approach to help you achieve optimal clinical outcomes in patients with chronic migraine14 >


CM: chronic migraine; CV: cardiovascular; ICHD: International Classification of Headache Disorders.

 

References

  1. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
  2. Allergan. Data on file. INT/0423/2016
  3. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
  4. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
  5. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/859/smpc.
  6. Davies P T G, Lane R J M et al. The long and winding road: the journey taken by headache sufferers in search of help. Prim Health Care Res Dev. 2019;20:e4
  7. Natoli J L, Manack A et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609
  8. National Institute for Health and Care Excellence (NICE). CG150: Headaches in over 12s: diagnosis and management. Available at: www.nice.org.uk. Accessed January 2025
  9. Schwedt T J. Chronic migraine. BMJ 2014;348:g1416
  10. National Institute of Health and Care Excellence (NICE) clinical knowledge summary (CKS). Migraine. Available at: https://cks.nice.org.uk. Accessed January 2025
  11. Buse D C, Manack A N et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456-1470
  12. Loder E, Rizzoli P. Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache. 2018;58(Suppl 3):218-229
  13. Woolley J M, Bonafede M M et al. Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache. 2017;57(9):1399-1408
  14. Blumenfeld A M, Silberstein S D et al. Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes. Headache. 2017;57(5):766-777

 

References

  1. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
  2. Allergan. Data on file. INT/0423/2016
  3. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
  4. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
  5. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk /emc/product/859/smpc.
  6. Davies P T G, Lane R J M et al. The long and winding road: the journey taken by headache sufferers in search of help. Prim Health Care Res Dev. 2019;20:e4
  7. Natoli J L, Manack A et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609
  8. National Institute for Health and Care Excellence (NICE). CG150: Headaches in over 12s: diagnosis and management. Available at: www.nice.org.uk. Accessed January 2025
  9. Schwedt T J. Chronic migraine. BMJ 2014;348:g1416
  10. National Institute of Health and Care Excellence (NICE) clinical knowledge summary (CKS). Migraine. Available at: https://cks.nice.org.uk. Accessed January 2025
  11. Buse D C, Manack A N et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456-1470
  12. Loder E, Rizzoli P. Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache. 2018;58(Suppl 3):218-229
  13. Woolley J M, Bonafede M M et al. Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache. 2017;57(9):1399-1408
  14. Blumenfeld A M, Silberstein S D et al. Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes. Headache. 2017;57(5):766-777

Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The BOTOX® Summary of Product Characteristics can be found here

By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk

Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

 

Date of preparation: January 2025. UK-BCM-240124.